0000000000294015

AUTHOR

Lambros Tselikas

0000-0002-8878-4916

showing 2 related works from this author

Imaging-guided interventions modulating portal venous flow: Evidence and controversies

2021

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalis…

HepatologyGastroenterologyInternal MedicineImmunology and AllergyALPPS associating liver partition and portal vein ligation for staged hepatectomy transjugular intrahepatic portosystemic shunt BSG British Society of Gastroenterology EASL European Association for the Study of the Liver FLR future liver remnant HE hepatic encephalopathy NCBA N-butyl cyanoacrylate PH portal hypertension PVE portal vein embolisation PVR portal vein recanalisation TIPS transjugular intrahepatic portosystemic shunt Portal vein interventions TACE trans-arterial chemoembolization portal vein recanalization RCT randomised controlled trial portal vein embolization portal hypertension image guidedJHEP Reports
researchProduct

Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment

2023

Purpose To investigate whether liver enhancing tumor burden (LETB) assessed at contrast-enhanced CT indicates early response and helps predict survival outcomes in patients with multifocal neuroendocrine liver metastases (NELM) after intra-arterial treatment. Materials and Methods This retrospective study included patients with NELM who underwent intra-arterial treatment with transarterial embolization (TAE) or chemoembolization (TACE) between April 2006 and December 2018. Tumor response in treated NELM was evaluated by using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST). LETB was measured as attenuation 2 SDs greater than that of a region of intere…

OncologyMale; Humans; Middle Aged; Tumor Burden; Retrospective Studies; Treatment Outcome; Chemoembolization Therapeutic/methods; Liver Neoplasms/diagnostic imaging; Liver Neoplasms/therapy; Tomography X-Ray Computed; Abdomen/GI; CT; Chemoembolization; Embolization; LiverRadiology Nuclear Medicine and imagingAbdomen/GI CT Chemoembolization Embolization LiverOriginal Research
researchProduct